A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Ki vehet részt

• Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria
• Previously received treatment for CLL/SLL with both a BTKi and a BCL2i
• Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• Adequate liver function
• Adequate blood clotting function

Ki nem vehet részt

• Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months
• Prior exposure to any BTK protein degraders
• Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
• Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
• Clinically significant cardiovascular disease
• Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period
• Known contraindications to azole antifungal agents, including hypersensitivity reactions
• Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years
• Known central nervous system involvement